PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Hannover Medical School, Institute of Immunology, Hannover, Germany.\', \'Institute of Molecular and Clinical Immunology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany.\', \'Research Center CHAMP (Center for Health And Medical Prevention), Otto-von-Guericke-University Magdeburg, Magdeburg, Germany.\', \'Health Campus Immunology, Infectiology and Inflammation (GC-I3), Medical Faculty, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany.\', \'German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.\', \'German Center for Lung Research (DZL), Hannover, Hannover, Germany.\', \'Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1002/eji.202149645
?:doi
?:hasPublicationType
?:journal
  • European journal of immunology
is ?:pmid of
?:pmid
?:pmid
  • 34870322
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.206
?:rankingScore_hIndex
  • 185
?:title
  • Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34870322>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34870322>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all